

Cell Reports Medicine, Volume 5

Supplemental information

**Proteo-metabolomics and patient tumor slice
experiments point to amino acid centrality
for rewired mitochondria in fibrolamellar carcinoma**

Donald Long Jr., Marina Chan, Mingqi Han, Zeal Kamdar, Rosanna K. Ma, Pei-Yin Tsai, Adam B. Francisco, Joeva Barrow, David B. Shackelford, Mark Yarchoan, Matthew J. McBride, Lukas M. Orre, Nathaniel M. Vacanti, Taranjit S. Gujral, and Praveen Sethupathy


Figure S1

Figure S1. Workflow diagram. Schematic of proteomic and metabolomic workflow. LC MS/MS = Liquid Chromatography Mass Spectrometry/Mass Spectrometry; ML = Machine Learning; DEqMS = Differential Expression of quantitative Mass Spectrometry ; XgBoost = Extreme Gradient Boost; CV = Cross-Validation; Adj = Adjusted; EBAM = Empirical Bayes Analysis of Microarrays. Omics-matched refers to patient samples that were present in both the proteomic and metabolomic datasets. **Related to STAR Methods.**









Figure S2

Figure S2. Machine learning using omics datasets performed significantly better than noise at tumor classification. Schematics that depict core principles of nested cross-validation for **(a)** proteomics and **(b)** metabolomics. Total samples for ($n_{\text{proteomics}} = 36; n_{\text{metabolomics}} = 36$) were split into a training set ($n_{\text{proteomics}} = 23$ and $n_{\text{metabolomics}} = 26$ samples that were used for analyses involving machine learning & beyond) and a hold-out set ($n_{\text{proteomics}} = 13$ and $n_{\text{metabolomics}} = 10$ additional, independent samples. These samples were used exclusively for machine learning). The data from the training and hold-out sets were processed independently, thereby minimizing data leakage. Training data went through two iterations of inner-loop train ($n_{\text{proteomics}} = 13$ and $n_{\text{metabolomics}} = 18$)/test ($n_{\text{proteomics}} = 10$ and $n_{\text{metabolomics}} = 8$) stratified splitting. With each iteration, the inner training (IT) data was subsetted for the most relevant features using a PCA-based method (see Methods). The subsetted IT data was subsequently used for stratified 2-fold,3-repeat cross validation (CV) where each fold (or resample) contained at least **(a)** six ($n_{\text{NML}} = 2; n_{\text{FLC}} \geq 4$) or **(b)** nine ($n_{\text{NML}} = 2; n_{\text{FLC}} = 7$) samples within each partition for training and testing. **(a,b)** Hyperparameter tuning was incorporated into the 2-fold,3-repeat CV. With each iteration, the best model from the inner training was assessed for performance against the inner test data. Overall evaluation of training performance was attained by averaging the **(a)** two or **(b)** three training assessments from the **(a)** two or **(b)** three iterations of inner training. The union of the feature subsets from the **(a)** two or **(b)** three iterations was used to subset the whole training dataset, and 2-fold,3-repeat CV with hyperparameter tuning was performed. A final evaluation was executed by assessing the performance of the trained model against the hold-out set. Bar plots displaying performance metrics generated from machine learning (ML) pipeline (see Methods for further details) using **(c,d)** proteomic and **(e,f)** metabolomic data as input. Performance metrics are associated with the **(c,e)** training phase or **(d,f)** testing phase of the machine learning algorithm. **(c-f)** Dot dash line represents threshold at which the model performs no better than random chance. Mann Whitney used for statistical analysis—*BH-adj pval < 0.05; **BH-adj pval < 0.01; *** BH-adj pval < 0.001. Permute_df_prebatchadj = permuted proteomics dataset without batch adjustment; Permute_df_postbatchadj = Batch-adjusted, permuted proteomics dataset; original_df_prebatchadj = original proteomics dataset without batch adjustment; original_df_postbatchadj = original proteomics dataset with batch adjustment; permuted_df_b4process = permuted metabolomics dataset prior to processing (prior to normalization, transformation, or co-variate adjustment); permuted_df_postprocess = permuted metabolomics dataset that has been processed; original_df_b4process = original metabolomics dataset prior to processing (prior to normalization, transformation, or co-variate adjustment); original_df_postprocess = original metabolomics dataset that has been processed; PR_AUC = precision-recall area under the curve; Round represents consecutive rounds of full pipeline (nested cross-validation) execution. For learning rate, lower values indicate better learning. **Related to STAR Methods.**






Figure S3

Figure S3. Macronutrient profile in FLC. Volcano plots and box plot show abundance of **(a)** proteins and **(b,c)** metabolites. **(a,b)** Highlighted datapoints and colored labels denote down-regulated (blue) or up-regulated (red) **(a)** proteins (fdr-adj $p < 0.05$; $n = 23$ samples) or **(b,c)** metabolites (fdr-adj $p < 0.1$; $n = 26$ samples). **Related to Figure 1.**











Figure S4

Figure S4. Proteo-transcriptomic signature and functional assessment of mitochondrial respiration suggests ETC dysfunction. (a) Comparison of log₂FCs (z-scaled) at the protein (x-axis; n = 23 samples) and RNA (y-axis; n = 27 samples) level. Density plots represent the distribution of the log₂FCs. Lines = median. Labeled datapoints = mitochondrially translated ETC subunits. Gene sets were compared to bkgd using Mann Whitney (**fdr- adj p < 0.01). Bkgd = Background. MitoCarta3.0 was used to identify gene sets. **(b)** MRC of ETC complexes in matched, frozen patient tissue per gram of protein (n = 6 samples per tissue type). Per gram protein is representative of collective MRC. RQV = relative quantitative value. **(c)** Assessment of MRC, SRC (spare respiratory capacity), and basal respiration (BR) of mitochondria in FLC cell line (n = 5 per trial). OCR = Oxygen consumption rate. **(d)** Abundance levels and ratios of ATP, ADP, and AMP from frozen patient tumor (FLC, n=20) and non-malignant liver (NML, n=6) tissue. **(e)** Descriptive model depicting dysfunction of mitochondrial respiration in FLC. **Related to Figure 3.**




c.

Clinical Features & Outcomes of Patients with FLC-Induced Hyperammonemia

| | Cases(Proportion) | Cases(Percentage) |
|---|-------------------|-------------------|
| Suspected OTC Deficiency | 11/18 | 61.1% |
| Confirmed OTC mutation | 0/11 | 0% |
| Positive Reponse to Arg Supplementation | 7/9 | 77.8% |
| Unreponsive to Arg Supplementation | 2/9 | 22.2% |

d.

FLC-Induced Hyperammonemia
Urea Cycle Intermediates



e.

Differential Protein Expression
Arg Consumers/Orn & Urea Producers





Figure S5

Figure S5. Rewiring of the TCA cycle is associated with urea cycle defects in FLC. **(a)** Concordance (n = 17 omics-matched sample pairs, 13 of which are FLC) between abundance of proteins (datapoints) and ornithine. Colored datapoints denote protein-metabolite pairs that are significantly ($-\log_{10}(\text{fdr-adj } p) > 1.3$) concordant (red) or discordant (blue) in FLC. Labeled datapoints represent the top four associations. Arrows adjacent to labels denote direction of significant alterations in the abundance of proteins (datapoints; $\text{fdr-adj } p < 0.05$) in FLC (n = 16 samples) compared to NML (n = 7 samples). Gray datapoints = no significance. **(b)** Volcano plot highlighting the abundance of key metabolites associated with OAT nexus. Highlighted datapoints associated with colored labels denote metabolites that display differential abundance in FLC (n = 20 samples) compared to NML (n = 6 samples). **(c)** Table depicting clinical features and outcomes from our meta-analysis of case studies involving patients with FLC-associated hyperammonemia encephalopathy (HAE). OTC = ornithine transcarbamylase; Arg = arginine. **(d)** Ammonia (serum; n = 14 cases) and amino acid (plasma; n = 10 cases) levels from case studies involving patients with FLC-associated HAE. Area between the dotted lines = reference range. **(e)** Differential protein expression of arginases in FLC (n = 16) compared to NML (n = 7)—* $\text{fdr-adj } p < 0.05$. **Related to Figure 6.**

a.



b.




Figure S6. Rewired OAT nexus in FLC may be to fuel ECM remodeling. (a) Descriptive model embedded with omics data (proteomics—n = 23 samples; metabolomics—n = 26 samples) depicting OAT nexus in FLC. Left side of each node—gradient red = increasing log₂FC (FLC vs NML) and gradient blue = decreasing log₂FC; right side of each node—gray = not significant and yellow = significant (proteins—fdr-adj p < 0.05; metabolites—fdr-adj p < 0.1); nodes associated with edges that have open circles = proteins; nodes associated with edges that have solid arrows = metabolites; ellipses = pathways; red arrow = hypothesized enhancement; blue arrow = hypothesized suppression. **(b)** Comparison of log₂FCs (FLC vs. NML; Z-Scaled) at protein (n=23 samples) and RNA (n=27 samples) level for genes that participate in extracellular matrix remodeling. Protein Atlas, Uniprot, and Reactome were used to identify gene sets. Gene sets were compared to bkgd using Mann Whitney test (*FDR adjusted p < 0.05; **fdr adjusted p < 0.01;***adjusted p<0.001;****adjusted p<0.0001). Background set (bkgd) is all genes identified in both omics' datasets. For the gene sets (excluding bkgd): circles = genes with no significant log₂FCs at either RNA or protein level; diamonds = genes with significant log₂FCs at both the RNA and protein level; triangles = genes with significant log₂FCs at protein level; squares = genes with significant log₂FCs at RNA level; shape size = average gene expression values (from transcriptomic data). **Related to Figure 7.**

Figure S7




Figure S7. Working model of FLC metabolism. Arrow size is directly associated with arrow color. Node size is arbitrary. Red = increase; green = neutral; blue = decrease; gray = no data; elliptical node = protein; square node = metabolite; arrow = reaction or transport; broken arrows = series of reactions; ROS = reactive oxygen species. Sections pertaining to ROS, GLUD, and electron transfer are implications of the model as opposed to direct data.
Related to Figures 1-7.